Back to Search
Start Over
Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Suboptimal Response to Ruxolitinib: Final Results From a Phase 2 Study
- Source :
- Blood. 140:579-582
- Publication Year :
- 2022
- Publisher :
- American Society of Hematology, 2022.
- Subjects :
- Immunology
Cell Biology
Hematology
Biochemistry
Subjects
Details
- ISSN :
- 15280020 and 00064971
- Volume :
- 140
- Database :
- OpenAIRE
- Journal :
- Blood
- Accession number :
- edsair.doi...........39ad9445dab952b350b044ff0d662bfd
- Full Text :
- https://doi.org/10.1182/blood-2022-160384